{"schema_version":"1.0","type":"article","title":"Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.md","lang":"en","date":"2026-08-16","publish_at":"2026-08-16T08:00:00+08:00","updated_at":"2026-08-16","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","obesity","weight-loss drugs","GLP-1","Pfizer","Roche","Amgen","Metsera","Caliway","ANYA Biopharm"],"summary":"Pfizer, Roche and Amgen are pruning obesity programs that lack clear differentiation. The GLP-1 market has moved from a race to enter the clinic to a contest across efficacy, safety, convenience and commercial execution.","key_points":[],"facts":[],"sections":["Another Wave of Obesity Drugs Falls: Ordinary Players No Longer Have a Ticket to the GLP-1 Market","01 | Pfizer: An Expensive Oral GLP-1 Portfolio, Cut Without Hesitation","02 | Roche and Amgen Are Pruning Too: No Advantage Is a Disadvantage","03 | Why Are Large Drugmakers Cutting So Aggressively? Phase 3 Is Expensive and the Market Is Crowded","04 | Cutting Ordinary Assets Does Not Mean Abandoning Obesity","05 | The Taiwan Read-Through: Caliway and ANYA Approach the Market from Different Angles","Conclusion | Obesity Drugs Are Not Cooling Down. The Bar Is Rising"],"references":[{"title":"[Fierce Biotech","source":"Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout]","date":"","url":"https://www.fiercebiotech.com/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout"},{"title":"[Pfizer","source":"Robust Phase 2b efficacy and favorable tolerability support monthly dosing for berobenatide]","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support"},{"title":"[Reuters","source":"Metsera shareholders vote for an acquisition by Pfizer valued at up to US$10 billion]","date":"","url":"https://www.investing.com/news/stock-market-news/metsera-shareholders-vote-for-10-billion-acquisition-by-pfizer-4355617"},{"title":"[Reuters","source":"What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?]","date":"","url":"https://finance.yahoo.com/news/factbox-metsera-target-pfizers-novo-170136393.html"},{"title":"[Roche","source":"Positive Phase 2 results for dual GLP-1/GIP receptor agonist CT-388]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-01-27"},{"title":"[BioSpace","source":"Roche cans one Carmot obesity asset as another shows best-in-class potential]","date":"","url":"https://www.biospace.com/business/roche-cans-one-carmot-obesity-asset-as-another-shows-best-in-class-potential"},{"title":"[Amgen","source":"Second-quarter 2026 financial results and pipeline update]","date":"","url":"https://www.amgen.com/newsroom/press-releases/2026/08/amgen-reports-second-quarter-2026-financial-results"},{"title":"[Terns Pharmaceuticals","source":"Topline Phase 2 data from TERN-601 in obesity]","date":"","url":"https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2/"},{"title":"[The New England Journal of Medicine","source":"Retatrutide for Obesity]","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972"},{"title":"[Caliway Biopharmaceuticals","source":"CBL-514 in combination with GLP-1R-based therapies at ADA 2026]","date":"","url":"https://www.caliwaybiopharma.com/en/news-detail/U-S-OI25-IND-CBL-514-ADA/"},{"title":"[Center Laboratories / ANYA Biopharm","source":"ANY-002 oral GLP-1 receptor agonist]","date":"","url":"https://www.centerlab.com.tw/en/industrial/company/21"},{"title":"Verification cut-off: 16 August 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | The obesity drug shakeout accelerates as ordinary programs lose their ticket to the GLP-1 market","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-01.png"},{"alt":"Figure 2 | The entry ticket for the next phase of GLP-1 competition spans efficacy, safety, convenience, comorbidity benefit, manufacturing and access","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-02.png"},{"alt":"Figure 3 | Pfizer, Roche and Amgen are concentrating resources on obesity assets that may still break through","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-03.png"},{"alt":"Figure 4 | Taiwan's adjacent opportunities: Caliway targets adipose remodeling and weight maintenance while ANYA tests the oral-peptide barrier","url":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-01.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-16）。Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?。https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}